Odyssey Therapeutics, a Boston MA-based biotechnology company advancing next generation precision immunomodulators and oncology medicines, raised $218M in Series A funding.
The round was led by OrbiMed Advisors and SR One Capital Management with participation from Foresite Capital, Woodline Partners LP, Logos Capital, HBM Healthcare Investments, Colt Ventures, Creacion Ventures and other institutional investors. Carl L. Gordon, Ph.D., Managing Partner of OrbiMed Advisors, will join Odyssey’s board of directors.
The company intends to use the funds to advance multiple pipeline programs and its discovery platform aimed at expanding the druggable genome.
Founded by Gary D. Glick, Ph.D., Odyssey develops a generation immunomodulators and oncology medicines by leveraging a discovery platform that combines target biology, medicinal and structural chemistry, physics-based molecular simulations, and AI/machine learning.
Led by a team of drug hunters and executives with a track record of accomplishment in helping to bring more than 20 drugs to market, the company aims to select targets and to determine the therapeutic modality that will have the greatest clinical impact.
With headquarters and labs in Boston, Odyssey is expanding with more than 90 scientists and staff.